References
- Product monograph for Xeloda® (capecitabine) tablets. 2010.
- Gelmon K, Chan A, Harbeck N. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist 2006;11:42–51.
- Cassidy J, Twelves C, Cameron D, Steward W, O’Byrne K, Jodrell D, Banken L, Goggin T, Jones D, Roos B, Bush E, Weidekamm E, Reigner B. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 1999;44:453–460.
- Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001;40:85–104.
- Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M, Osterwalder B. Effect of food on the pharmacokinetics of capacitance and its metabolites following oral administration in cancer patients. Clin Cancer Res 1998;4:941–948.
- Mendes GD, Babadopulos T, Chen LS, Ilha JO, de Almeida Magalhães JC, Alkharfy K, Nucci GD. The use of healthy volunteers to evaluate bioequivalence of antineoplasic drugs: pilot studies with capecitabine. J Bioequiv Availab 2011;S1:1–8.
- Office of Generic Drugs. Draft guidance on capecitabine. (Recommended July 2008; Revised Aug 2010; Sep 2012). Available online at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm083276.pdf, accessed 05 February 2011.
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
- Assessment report, Capecitabine Teva, Procedure No. EMEA/H/C/002362. 2012.